Vesugen
Vascular bioregulator peptide
Vascular tissue bioregulator.
Half-life
~ hours
Mol. weight
~ 376.4 g/mol
Sequence
Lys-Glu-Asp (KED)
Discussions
0 threads
Overview
A short bioregulator peptide studied for regulating gene expression in vascular (blood vessel) tissue, with proposed support for endothelial function. It applies the Khavinson bioregulator framework to the vasculature — targeting the endothelium whose age-related dysfunction underlies much of cardiovascular aging.
Mechanism of action
Vesugen is a bioregulator peptide studied for regulating gene expression in vascular tissue, with proposed support for endothelial function. Vascular aging — the gradual stiffening and endothelial dysfunction of blood vessels — is central to cardiovascular disease and to aging broadly, since healthy endothelium underlies organ perfusion across every system. Vesugen applies the Khavinson ultra-short-peptide framework to that target. The target organ is undeniably important; the bioregulator evidence base is limited and concentrated in one tradition.
Researched benefits
- Studied for vascular/endothelial support
- Targets a tissue central to cardiovascular aging
- Short bioregulator format
Considerations
- Vascular disease requires medical care
- Evidence concentrated in one tradition
- Human data limited
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Vesugen in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Vesugen:
View Vesugen index on PubMed (NCBI)